Zentalis Total Stockholder Equity vs Non Current Liabilities Total Analysis

ZNTL Stock

USD 11.06 0.07 0.64%

Zentalis PharmaceuticalsL financial indicator trend analysis is more than just analyzing Zentalis PharmaceuticalsL current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zentalis PharmaceuticalsL is a good investment. Please check the relationship between Zentalis PharmaceuticalsL Total Stockholder Equity and its Non Current Liabilities Total accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis PharmaceuticalsLlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Total Stockholder Equity vs Non Current Liabilities Total

Total Stockholder Equity vs Non Current Liabilities Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zentalis PharmaceuticalsL Total Stockholder Equity account and Non Current Liabilities Total. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Zentalis PharmaceuticalsL's Total Stockholder Equity and Non Current Liabilities Total is 0.89. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Zentalis PharmaceuticalsLlc, assuming nothing else is changed. The correlation between historical values of Zentalis PharmaceuticalsL's Total Stockholder Equity and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Zentalis PharmaceuticalsLlc are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Total Stockholder Equity i.e., Zentalis PharmaceuticalsL's Total Stockholder Equity and Non Current Liabilities Total go up and down completely randomly.

Correlation Coefficient

0.89

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Non Current Liabilities Total

Most indicators from Zentalis PharmaceuticalsL's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zentalis PharmaceuticalsL current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis PharmaceuticalsLlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Tax Provision is expected to rise to about (784.7 K) this year. The value of Selling General Administrative is expected to slide to about 56.4 K

	2010	2019	2023	2024 (projected)
Interest Income	355K	498K	572.7K	469.2K
Net Interest Income	355K	498K	572.7K	469.2K

Interest Income Net Interest Income

Zentalis PharmaceuticalsL fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.98	0.98	1.0	0.11	0.96	0.91	0.52	-0.88	0.99	0.4	0.88	0.36	0.91	1.0	0.84	-0.47	-0.87	0.96	0.92	0.99	0.98	0.96	1.0	0.76	1.0
Other Current Liab	0.98		1.0	0.96	0.22	0.93	0.92	0.58	-0.92	0.98	0.33	0.87	0.38	0.93	0.97	0.89	-0.51	-0.83	0.97	0.96	0.99	1.0	0.99	0.96	0.75	0.97
Total Current Liabilities	0.98	1.0		0.97	0.19	0.94	0.92	0.58	-0.92	0.99	0.34	0.87	0.42	0.93	0.98	0.89	-0.52	-0.84	0.97	0.96	0.99	1.0	0.99	0.97	0.77	0.98
Total Stockholder Equity	1.0	0.96	0.97		0.1	0.96	0.89	0.48	-0.87	0.98	0.42	0.86	0.35	0.9	1.0	0.81	-0.46	-0.88	0.95	0.89	0.98	0.97	0.94	1.0	0.74	1.0
Other Liab	0.11	0.22	0.19	0.1		-0.03	0.02	-0.33	-0.13	0.07	0.42	-0.05	-0.13	-0.01	0.13	0.05	0.05	-0.33	0.31	0.08	0.13	0.19	0.14	0.14	-0.25	0.13
Net Tangible Assets	0.96	0.93	0.94	0.96	-0.03		0.86	0.65	-0.94	0.96	0.27	0.83	0.5	0.97	0.96	0.9	-0.66	-0.82	0.91	0.88	0.95	0.94	0.92	0.95	0.81	0.96
Property Plant And Equipment Net	0.91	0.92	0.92	0.89	0.02	0.86		0.61	-0.82	0.91	0.33	0.99	0.25	0.89	0.87	0.86	-0.39	-0.74	0.84	0.98	0.95	0.9	0.96	0.89	0.81	0.88
Net Debt	0.52	0.58	0.58	0.48	-0.33	0.65	0.61		-0.72	0.57	-0.48	0.56	0.41	0.77	0.49	0.82	-0.63	-0.14	0.43	0.67	0.59	0.57	0.63	0.45	0.6	0.5
Retained Earnings	-0.88	-0.92	-0.92	-0.87	-0.13	-0.94	-0.82	-0.72		-0.91	-0.18	-0.76	-0.63	-0.98	-0.88	-0.97	0.8	0.75	-0.91	-0.88	-0.89	-0.92	-0.91	-0.86	-0.81	-0.88
Accounts Payable	0.99	0.98	0.99	0.98	0.07	0.96	0.91	0.57	-0.91		0.34	0.87	0.48	0.93	0.98	0.86	-0.53	-0.85	0.96	0.94	0.98	0.99	0.97	0.98	0.82	0.98
Cash	0.4	0.33	0.34	0.42	0.42	0.27	0.33	-0.48	-0.18	0.34		0.37	0.06	0.16	0.39	0.08	0.0	-0.76	0.48	0.25	0.33	0.33	0.3	0.47	0.28	0.39
Non Current Assets Total	0.88	0.87	0.87	0.86	-0.05	0.83	0.99	0.56	-0.76	0.87	0.37		0.21	0.85	0.84	0.81	-0.34	-0.73	0.79	0.95	0.92	0.85	0.92	0.87	0.81	0.84
Non Currrent Assets Other	0.36	0.38	0.42	0.35	-0.13	0.5	0.25	0.41	-0.63	0.48	0.06	0.21		0.53	0.38	0.52	-0.85	-0.4	0.48	0.35	0.31	0.42	0.39	0.36	0.72	0.38
Other Assets	0.91	0.93	0.93	0.9	-0.01	0.97	0.89	0.77	-0.98	0.93	0.16	0.85	0.53		0.9	0.98	-0.73	-0.74	0.88	0.92	0.93	0.92	0.93	0.89	0.84	0.9
Cash And Short Term Investments	1.0	0.97	0.98	1.0	0.13	0.96	0.87	0.49	-0.88	0.98	0.39	0.84	0.38	0.9		0.82	-0.48	-0.88	0.97	0.89	0.98	0.98	0.95	0.99	0.73	1.0
Net Receivables	0.84	0.89	0.89	0.81	0.05	0.9	0.86	0.82	-0.97	0.86	0.08	0.81	0.52	0.98	0.82		-0.76	-0.65	0.83	0.9	0.88	0.88	0.91	0.81	0.81	0.83
Good Will	-0.47	-0.51	-0.52	-0.46	0.05	-0.66	-0.39	-0.63	0.8	-0.53	0.0	-0.34	-0.85	-0.73	-0.48	-0.76		0.45	-0.55	-0.46	-0.46	-0.52	-0.5	-0.45	-0.69	-0.48
Common Stock Total Equity	-0.87	-0.83	-0.84	-0.88	-0.33	-0.82	-0.74	-0.14	0.75	-0.85	-0.76	-0.73	-0.4	-0.74	-0.88	-0.65	0.45		-0.92	-0.73	-0.83	-0.84	-0.8	-0.91	-0.68	-0.88
Common Stock Shares Outstanding	0.96	0.97	0.97	0.95	0.31	0.91	0.84	0.43	-0.91	0.96	0.48	0.79	0.48	0.88	0.97	0.83	-0.55	-0.92		0.88	0.94	0.98	0.94	0.96	0.74	0.97
Non Current Liabilities Total	0.92	0.96	0.96	0.89	0.08	0.88	0.98	0.67	-0.88	0.94	0.25	0.95	0.35	0.92	0.89	0.9	-0.46	-0.73	0.88		0.96	0.94	0.99	0.89	0.81	0.89
Other Current Assets	0.99	0.99	0.99	0.98	0.13	0.95	0.95	0.59	-0.89	0.98	0.33	0.92	0.31	0.93	0.98	0.88	-0.46	-0.83	0.94	0.96		0.98	0.98	0.98	0.75	0.98
Other Stockholder Equity	0.98	1.0	1.0	0.97	0.19	0.94	0.9	0.57	-0.92	0.99	0.33	0.85	0.42	0.92	0.98	0.88	-0.52	-0.84	0.98	0.94	0.98		0.98	0.97	0.75	0.98
Total Liab	0.96	0.99	0.99	0.94	0.14	0.92	0.96	0.63	-0.91	0.97	0.3	0.92	0.39	0.93	0.95	0.91	-0.5	-0.8	0.94	0.99	0.98	0.98		0.94	0.8	0.95
Net Invested Capital	1.0	0.96	0.97	1.0	0.14	0.95	0.89	0.45	-0.86	0.98	0.47	0.87	0.36	0.89	0.99	0.81	-0.45	-0.91	0.96	0.89	0.98	0.97	0.94		0.74	0.99
Property Plant And Equipment Gross	0.76	0.75	0.77	0.74	-0.25	0.81	0.81	0.6	-0.81	0.82	0.28	0.81	0.72	0.84	0.73	0.81	-0.69	-0.68	0.74	0.81	0.75	0.75	0.8	0.74		0.73
Total Current Assets	1.0	0.97	0.98	1.0	0.13	0.96	0.88	0.5	-0.88	0.98	0.39	0.84	0.38	0.9	1.0	0.83	-0.48	-0.88	0.97	0.89	0.98	0.98	0.95	0.99	0.73

Click cells to compare fundamentals

Zentalis PharmaceuticalsL Account Relationship Matchups

Zentalis PharmaceuticalsL fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	102.7M	365.6M	454.5M	539.3M	562.0M	378.6M
Other Current Liab	9.8M	19.0M	30.9M	45.4M	51.5M	29.2M
Total Current Liabilities	14.9M	28.6M	43.9M	56.6M	69.4M	40.3M
Total Stockholder Equity	76.8M	333.4M	364.5M	434.0M	437.3M	306.3M
Other Liab	4.2M	2.5M	1.6M	3.5M	3.1M	2.3M
Net Tangible Assets	(92.6M)	296.0M	360.2M	433.8M	498.9M	523.8M
Property Plant And Equipment Net	2.8M	3.6M	52.8M	50.1M	41.7M	27.8M
Net Debt	(81.6M)	(53.0M)	(13.8M)	2.1M	17.7M	18.6M
Retained Earnings	(83.0M)	(200.8M)	(359.6M)	(596.4M)	(888.6M)	(844.1M)
Accounts Payable	4.3M	8.7M	11.6M	11.2M	14.9M	9.9M
Cash	82.4M	55.0M	59.7M	43.1M	28.0M	39.1M
Non Current Assets Total	18.6M	20.5M	103.7M	87.4M	65.3M	56.8M
Non Currrent Assets Other	2.2M	2.3M	2.6M	(1.8M)	6.8M	7.2M
Other Assets	0.0	4.3M	9.7M	12.4M	14.2M	14.9M
Cash And Short Term Investments	82.4M	338.5M	339.9M	437.4M	482.9M	312.8M
Net Receivables	140K	417K	4.4M	7.0M	8.1M	8.5M
Common Stock Total Equity	25K	41K	45K	59K	53.1K	50.4K
Common Stock Shares Outstanding	35.9M	41.0M	42.7M	52.9M	65.4M	46.9M
Liabilities And Stockholders Equity	102.7M	365.6M	454.5M	539.3M	562.0M	378.6M
Non Current Liabilities Total	4.2M	3.6M	46.1M	48.6M	55.3M	29.4M
Capital Lease Obligations	781K	2.0M	45.9M	45.2M	43.2M	25.1M
Other Current Assets	1.5M	6.2M	10.9M	14.6M	13.8M	8.7M
Other Stockholder Equity	159.7M	534.1M	724.1M	1.0B	1.3B	691.8M
Total Liab	19.1M	32.2M	90.0M	105.3M	124.6M	69.6M
Net Invested Capital	76.8M	308.6M	364.0M	433.8M	437.3M	290.6M
Property Plant And Equipment Gross	2.8M	3.6M	53.6M	7.7M	44.9M	47.1M
Total Current Assets	84.1M	345.1M	350.8M	451.9M	496.7M	321.8M
Accumulated Other Comprehensive Income	(141.7M)	36K	(125K)	(1.4M)	2.2M	2.3M
Capital Stock	25K	41K	45K	59K	70K	66.5K
Net Working Capital	69.2M	316.5M	306.8M	395.3M	427.4M	281.5M
Common Stock	25K	41K	45K	59K	70K	66.5K
Property Plant Equipment	2.8M	3.6M	8.1M	7.7M	8.9M	5.0M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zentalis PharmaceuticalsL in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zentalis PharmaceuticalsL's short interest history, or implied volatility extrapolated from Zentalis PharmaceuticalsL options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GM	General Motors
S	SentinelOne
MSFT	Microsoft

When determining whether Zentalis PharmaceuticalsL is a strong investment it is important to analyze Zentalis PharmaceuticalsL's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis PharmaceuticalsL's future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:

How To Invest In Zentalis

Details

Is Zentalis Stock a good investment?

Details

What is Zentalis PharmaceuticalsL's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis PharmaceuticalsLlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Zentalis Stock analysis

When running Zentalis PharmaceuticalsL's price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.

	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Transaction History View history of all your transactions and understand their impact on performance
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum

Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.47)

Return On Assets

(0.29)

Return On Equity

(0.67)

The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis PharmaceuticalsL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zentalis Total Stockholder Equity vs Non Current Liabilities Total Analysis

Total Stockholder Equity vs Non Current Liabilities Total

Total Stockholder Equity vs Non Current Liabilities Total Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Non Current Liabilities Total

Zentalis PharmaceuticalsL fundamental ratios Correlations

Zentalis PharmaceuticalsL Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zentalis PharmaceuticalsL fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Zentalis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Other Stockholder Equity	+ 1.0	Other Current Liab

Other Assets	- 0.98	Retained Earnings
Net Receivables	- 0.97	Retained Earnings
Retained Earnings	- 0.94	Net Tangible Assets
Common Stock Shares Outstanding	- 0.92	Common Stock Total Equity
Other Stockholder Equity	- 0.92	Retained Earnings
Retained Earnings	- 0.92	Total Current Liabilities